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ABSTRACT  
The emergence of single molecule localization microscopy 
(SMLM) techniques made the imaging of cells at 
resolutions far beyond the diffraction barrier possible. 
However, the usual approach of tagging a protein of 
interest (PoI) with a primary antibody, and tagging this one 
with a fluorophore-carrying secondary antibody, 
introduces a significant displacement of the signal from the 
PoI. Here, the generation and application of an αGFP-
nanobody is described which, through its reduced size and 
direct fluorophore labeling, leads to a much higher co-
localization of signal and PoI and qualifies for dSTORM 
imaging of nuclear proteins. 
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INTRODUCTION 
Fluorescence microscopy is a technique that exploits the 
quantumphysical characteristics of fluorescent molecules 
(FMs) and that allows imaging of proteins of interest 
within a cell. In short, FMs are irradiated with 
electromagnetic (EM) waves of certain wavelengths within 
the range of visible light, pushing them into an excited 
energy level. As the molecules return to their ground state, 
they emit energy again in the form of an EM wave of a 
slightly longer wavelength, which can then be detected. 
However, as described by Abbe’s Law, the minimum 
distance between two points with overlapping signals 
needed to still be distinguishable is directly proportional to 
their wavelength, which leads us to a resolution limit for 
conventional fluorescence microscopy of about a third of 
the wavelength of the laser[1].  
Single molecule localization microscopy (SMLM) 
techniques break this so-called diffraction barrier. In the 
case of direct stochastic optical reconstruction microscopy 
(dSTORM) this is done by taking advantage of another, 
more stable energy level called the dark state, that leads to 
a large portion of FMs to be ‘switched off’ and only 
stochastically return to a fluorescent state, resulting in the 
individual detection of single molecules with a precision 
of tens of nanometers[2]. This technique relies heavily on 
particular characteristics of fluorophores such as their ratio 
between OFF and ON time and the number of switching 
cycles they can go through before permanent 
photobleaching. Furthermore, while extremely high 
resolution can be achieved, FMs are usually conjugated to 
secondary antibodies, which introduces significant label 
displacement and thus the detected signal can still be 
around 30nm from the actual location of the protein of 
interest, making it hard to determine the exact morphology 
and structure of complexes such as protein filaments on 
DNA[3]. Nanobodies are antibody fragments consisting of 
only the epitope-binding domain, which are considerably 
smaller with a diameter of around 2-4nm[4]. Here, the 
generation of a GFP-specific nanobody labeled with far-
red fluorescent dye suitable for STORM imaging is 
described, which can be used to produce super-resolution 
images of even nuclear proteins that are tagged with GFP 
with minimal label displacement.  
MATERIALS AND METHODS 
αGFP-nanobody expression and purification 
The pOPINE GFP nanobody was a gift from Brett Collins 
(Addgene plasmid # 49172)[5]. An additional Cysteine 
residue was introduced at the C-terminus through PCR, as 
well as a His6-tag and a TEV cleaving site at the N-
terminus, and the PCR fragment was then cloned into a 
pETM-11 carrier plasmid with a kanamycin-resistance 
selection marker through Gibson assembly[6]. The 
nanobody contains two internal (at positions 23 and 79) 
and one additional Cysteine residue that was inserted at the 
C-terminus. The maleimide-conjugated far-red fluorescent 
dye used in this project can react with the accessible 
additional thiol group of the inserted Cys-residue in order 
to label the nanobody. A carrier plasmid (pETM-11) was 
digested with NcoI and XhoI restriction enzymes and 
column purified with Zeba SpinColumns. For the assembly 
reaction, 1μL of linearized plasmid DNA and 1μL of the 
nanobody insert were added to 2μL of 2x Gibson 
Assembly mix and then heated to 50°C for 1h. The plasmid 
was then amplified in E. coli (strain DH5a). The 4μL 
reaction volume were mixed with 50μL of cells, put on ice 
for 30 minutes, then heat shocked at 42°C for 45 seconds. 
Subsequently, 800μL of LB was added and the cells were 
incubated for 1h at 37°C. The transformed bacteria were 
grown overnight on LB-Kanamycin plates. 10 single 
colonies were resuspended in 2.5mL LB-Kanamycin and 
again incubated overnight at 37°C. Plasmid DNA was 
subsequently extracted through miniprep. Successful 
insertion of the nanobody sequence at the target site was 
confirmed by a restriction digest reaction and Sanger 
sequencing.  
The retrieved plasmid was used to transform E. coli (strain 
BL21) in a similar fashion for a 5mL overnight culture in 
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 selective medium and incubated at 37°C until it reached 
log-phase. 0.5mM IPTG (final concentration) was added 
to induce protein expression for 19h at 20°C. The culture 
was centrifuged and the pellet was resuspended in equal 
volume of lysis buffer (500mM NaCl, 20mM HEPES, 
10mM Imidazole, 0.5mM DTT, 1x c0mplete protease 
inhibitor). After 45 min of ultra-centrifugation at 60,000x 
g, 1.5mL Ni-NTA Agarose beads (Invitrogen) were added 
to the supernatant and mixed for 1h at 4°C. The sample 
was added to a separating column, washed twice with 
washing buffers (20mM HEPES, 0.5M DTT, and 500mM 
NaCl with 20mM Imidazole or 250mM NaCl with 40mM 
Imidazole respectively) and finally eluted in 17 fractions 
of 1mL each with an elution buffer (250mM NaCl, 20mM 
HEPES, 250mM Imidazole, 0.5mM DTT). The fractions 
with the highest amount of nanobody were pooled and 
stored at -80°C.  
Conjugation of nanobody and fluorescent dye 
For the labeling reaction, 340μL of protein (40nmoles) 
were first reduced by adding 60μL of 100mM TCEP, 
resulting in a final concentration of 15mM, for 10 min on 
ice. Next, the buffer was exchanged into maleimide 
labeling buffer (0.1M potassium phosphate, 150mM NaCl, 
1mM EDTA, 2.5mM sucrose, pH 6.4[3]) using ZebaSpin 
Columns (MWCO 7kDa, ThermoFisher). 12μL of CF647 
maleimide dye (10mM in anhydrous DMSO, Biotium) was 
added, leading to a 3x molar excess in dye. Immediately 
upon thorough mixing, 60μL 1M K2HPO4 were added to 
neutralize the reaction by raising the pH to 7.5. The sample 
was left on ice for 1.5h before applying it to a VivaSpin 
concentrator column (MWCO 5kDa, SigmaAldrich) for 
buffer exchange into phosphate-buffered saline (PBS), 
clearance of free dye and concentration of the sample.  
Verification of GFP-binding activity 
To confirm that the fluorescent label does not impair the 
binding capacity of the nanobody to GFP, size-exclusion 
chromatography was performed using an ÄKTAmicro 
FPLC system with an S75 column with an approximate 
volume of 2.4mL. Here, larger molecules elute sooner 
from the column and can be detected by measuring the 
absorbance at particular wavelengths. After washing with 
PBS, 5 samples were injected and analyzed separately 
based on the absorbance at 280nm (protein), 488 nm (GFP) 
and 650nm (fluorescent dye). The samples inserted 
contained 2μM GFP, 2.5μM αGFP-nanobody, 2.5μM 
labeled nanobody, or mixtures of GFP with labeled or GFP 
with unlabeled nanobody respectively at the same 
concentrations in 60μL PBS. GFP-binding activity of the 
labeled nanobody would be visualized as a shift of the 
488nm absorbance peak (GFP) and a shift of the original 
peak for absorbance at 650nm (fluorescent dye) towards a 
second peak that overlaps with the 488nm peak, as the 
larger GFP-nanobody complex would elute from the 
column sooner.  
Immunostaining 
The αGFP-nanobody was tested in mouse embryonic stem 
(mES) cell lines (strain IB10) expressing PCNA-GFP or 
BRCA2-GFP, both nuclear proteins, but expressed at 
different protein levels (BRCA2 estimated at around 3-
15nM in mES cells[7]). For control purposes, cells were 
alternatively stained with commercial αGFP-nanobody-
ATTO647 (GFP-Booster ATTO647N, Chromotek, 1:300), 
which is not suitable for dSTORM imaging. All cells were 
fixed for 15 minutes with 2% paraformaldehyde prior to 
staining. However, De Groever et al. (2010) show that due 
to its small size, the nanobody can also be applied in in 
vivo imaging[8|.  
0.5x106 cells were seeded overnight on 24mm glass cover 
slips (thickness 170μm) coated with laminin. They were 
fixed for 15 minutes with 2% paraformaldehyde in PBS. 
They were permeabilized by washing them three times 
short and twice for 10 minutes with 0.1% PBS+triton-
X100 (SigmaAldrich), and subsequently incubated for 
blocking at room temperature with PBS + 2% BSA + 
0.15% glycerol for 30 minutes in order to minimize non-
specific binding of the nanobody. The cover slips were 
incubated face-down on 150μL droplets of the blocking 
solution containing 50nM of the labeled nanobodies in a 
dark box for 30 minutes. Finally, the cells were washed 
again with PBS+triton-X100 and the cover slips were 
stored at 4°C in PBS.  
Confocal and dSTORM imaging 
Confocal and super-resolution imaging was performed 
using a Zeiss Elyra PS.1 microscope with an alpha Plan-
Apochromat 100x oil immersion objective (numerical 
aperture 1.46) and the ZEN 2012 SP5 FP1 software. The 
signal was detected with an EMCCD Andor iXon DU 897 
camera with an effective pixel size of 100*100nm. 
For confocal imaging, the cover slip was loaded onto a 
microscope ring and 1mL of PBS was added. Images were 
taken with a bandpass filter (650-700nm) as z-stacks of 11 
slides with a distance of 0.45μM, and for visualization of 
the foci, the maximum projection of this image stack was 
generated in ImageJ[9]. 
In the case of dSTORM imaging, a 655nm long-pass filter 
was used for the detection of the αGFP-nanobody-CF647. 
In order to increase the stability of the dark state for 
dSTORM imaging, the cells were loaded onto the 
microscope ring in 2 mL dSTORM buffer (containing 10% 
glucose, 50mM TRIS, 5mM NaCl, 25mM MEA and an 
oxygen scavenging compound consisting of glucose 
oxidase and catalase) and covered with an additional glass 
cover slip to reduce the contact with air and possible 
uptake of new oxygen. A 642nm laser was used to excite 
the CF647 dye and the intensity was adjusted until blinking 
of the molecules could be observed. A 405nm laser was 
added when necessary, as it has been shown that 
electromagnetic waves around 400nm are suitable for 
reverting molecules from the dark state to the fluorescent 
state[2]. dSTORM images were taken in time series of 
20,000 frames with an exposure time of 25ms and with the 
illumination source at a TIRF angle between 63° and 65°.  
 
RESULTS 
Nanobody labeling and functionality 
In order to determine the efficiency of the labeling 
reaction, SDS-polyacrylamide gel electrophoresis was 
performed. The labeled and unlabeled nanobody were 
visible in separate bands due to a difference in size and 
could be visualized by staining with colloidal coomassie. 
The intensity of the bands was measured in ImageJ three 
times, corrected for background, averaged, and the 
labeling efficiency could be calculated as the ratio of 
intensity of labeled to unlabeled nanobody. By this 
method, labeling efficiencies between 60-70% were 
determined.  
 
Figure 1: SDS-
PAGE stained 
with colloidal 
coomassie. V1 
and V2 describe 
the first and 
second round of 
the VivaSpin 
column. The 
upper band 
shows the labeled 
and the lower 
band unlabeled 
nanobody. 
The GFP-binding activity of the labeled nanobody was 
tested as described above (Fig. 2). As expected, mixing 
GFP with the αGFP-nanobody resulted in a shift of the 
488nm peak as well as a partial redistribution of the 650nm 
peak, co-localizing with the 488nm peak, which indicates 
that binding takes place. The second peak in the 650nm 
adsorption graph represents unbound αGFP-nanobody-
CF647, caused by a molar excess and a binding efficiency 
below 100%, and could possibly shrink by adjusting the 
molar ratios and a longer incubation time before injection 
into the column. The observed binding activity was similar 
to that of unlabeled nanobody (data not shown).  
 
Figure 2: Adsorption peaks of size-exclusion 
chromatography of 2μM GFP and 2:2.5μM GFP: αGFP-
nanobody-CF647 mixture. The y-axis describes the 
absorbance in mAU, the x-axis shows the eluted volume in 
mL. 
Qualification of the labeled nanobody for dSTORM 
imaging 
PCNA-GFP or BRCA2-GFP expressing cells were 
immunostained and prepared as described above.  
For both PCNA and BRCA2, foci were clearly visible 
under the confocal microscope (Fig. 3). The absence of 
foci in the wild-type cells indicates that the αGFP-
nanobody does not show any non-specific binding activity. 
 
Figure 3: Maximum projections of z-stack from confocal 
imaging: staining with 50nM αGFP-nanobody-CF647 of 
mouse ES cells expressing BRCA2-GFP (a), PCNA-GFP (b) 
or no GFP-tagged protein (wild-type, c) 
The detected CF647-signal co-localized with the GFP. The 
signal quality and patterning of the foci were similar to a 
control using a commercial αGFP-nanobody-ATTO647 
construct, which is not as suitable for dSTORM imaging, 
but the cells stained with the nanobody-CF647 showed a 
stronger background fluorescence (Fig. 4). 
 
Figure 4: Maximum projections of z-stack from confocal 
imaging of BRCA2-GFP expressing mouse ES cells: GFP 
signal (a), αGFP-nanobody-CF647 (b), αGFP-nanobody-
ATTO647 (c). a and b show the same field of view.  
BRCA2-GFP expressing and wild-type cells were also 
stained with 50nM of free CF647 dye and with PBS as a 
negative control to exclude autofluorescence as a cause of 
background fluorescence (Fig. 5). The absence of any 
signal in the control but evenly distributed fluorescence in 
the nucleus in the cells stained with CF647 leads to the 
assumption that the background signal observed in the 
cells stained with the labeled nanobody is caused by free 
dye that has not fully been eliminated in the sample.  
 
 
Figure 5: Maximum projections of z-stack from confocal 
imaging: BRCA2-GFP expressing mouse ES cells (a) and WT 
mouse ES cells (b) stained with 50nM CF647 dye, negative 
control of WT mouse ES cells with PBS (c). 
dSTORM imaging of BRCA2-GFP cells with αGFP-
nanobody-CF647 gave sufficient signal with mean and 
median precision levels of around 25nm, similar to those 
observed when imaging RAD51 using commercial 
 αRabbit F(ab’)2-CF568 antibody (SigmaAldrich), and 
could successfully be used for the detection and analysis of 
the morphology of BRCA2 structures at DNA damage 
sites in mES cells (Fig. 6). 
Figure 6: (a) 
dSTORM image of 
mES cell expressing 
BRCA2-GFP and 
stained with αGFP-
nanobody-CF647 2h 
after treatment with 
5Gy ionizing 
radiation, corrected 
for drift and with a 
signal intensity 
threshold of 2x 
standard deviation. 
(b) Discrete 
localizations of 
CF647 signal in the 
indicated section 
after filtering by 
means of a precision 
threshold and 
Voronoi tessellation.  
 
CONCLUSION 
The αGFP-nanobody-CF647 construct provides an easy 
way to image any GFP-tagged protein in a cell. The 
expression in and purification from E. coli cultures makes 
it a fast and cost-efficient procedure that doesn’t require 
any additional animal sacrifice and is easily reproducible. 
The labeling reaction follows a simple protocol and since 
the fluorescent dye is directly conjugated with the 
nanobody, there is no need for a secondary antibody, which 
makes  the immunostaining protocol faster and cheaper. 
The final construct still showed GFP-binding activity 
comparable to the unlabeled nanobody, indicating that the 
dye does not affect the interaction with the target protein. 
With GFP being a widely used fluorescent protein, many 
cell lines for GFP-tagged proteins of interest already exist 
or can be generated comparably easily, which allows for 
the use of this contruct in a wide variety of target proteins. 
Due to its suitability for dSTORM imaging, the described 
nanobody construct can be used to generate super-
resolution data with extremely high precision while 
minimizing the significant loss in accuracy caused by the 
label displacement that comes with the use of antibodies.    
In order to further improve the labeling efficiency, 
different adjustments to the labeling buffer or further 
purification, reduction and similar preparation steps could 
be tested. The free dye causing background signal could be 
better eliminated by more or different purification 
columns, or by gel-filtration, where the free dye would 
elute from the resin separately from the labeled nanobody 
due to the large size difference. Furthermore, a more 
suitable blocking solution, with blocking agents that have 
chemical structures more similar to that of the dye, might 
further reduce the background signal caused by sticky free 
dye. In this project, the nanobodies were not tested for the 
ability to penetrate the nuclear membrane in vivo, which 
would be useful for life cell imaging of nuclear processes.  
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